Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 79

Sort by

Sort Order Select

Journal Articles

A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

N. Nora Bennani, MD, Levi D Pederson, Pamela Atherton, Ivana Micallef, MD, Joseph P. Colgan, MD, Gita Thanarajasingam, MD, Grzegorz Nowakowski, MD, Thomas E. Witzig, MD, Andrew L. Feldman, MD, Stephen M Ansell, MD

Blood (2019) 134 (Supplement_1): 467.

https://doi.org/10.1182/blood-2019-126194

Published: 2019

Journal Articles

STAT3 Mutations and Anemia with Pure Red Cell Aplasia Are the Distinctive Features of T Cell Receptor Gamma Delta Type Large Granular Lymphocyte Leukemia

Taku Yamane, Toru Kawakami, MD, Nodoka Sekiguchi, MD PhD, Jun Kobayashi, Toshimitsu Ueki, MD, Hikaru Kobayashi, MD PhD, Sayaka Nishina, Kaoko Sakai, MD, Hitoshi Sakai, MD, Kazuo Oshimi, MD, Yumiko Higuchi, PhD, Hideyuki Nakazawa, MD PhD, Fumihiro Ishida, MD PhD

Blood (2019) 134 (Supplement_1): 1500.

https://doi.org/10.1182/blood-2019-123614

Published: 2019

Journal Articles

Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation

Namrata S Chandhok, MD, Scott F. Huntington, MD MPH, Iris Isufi, MD, Lohith Gowda, MD MRCP, Mina L Xu, MD, Noffar Bar, MD, Stuart Seropian, MD, Francine M. Foss, MD

Blood (2019) 134 (Supplement_1): 4055.

https://doi.org/10.1182/blood-2019-128888

Published: 2019

Journal Articles

Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas

Alex F. Herrera, MD, Jasmine Zain, MD, Kerry J Savage, BSc, MD MSc, Tatyana A. Feldman, MD, Jonathan E Brammer, MD, Lu Chen, PhD, Leslie L. Popplewell, MD FRCPA, Lihua E Budde, MD PhD, Lacolle Peters, Yaira Kurtzman, Stephen J Forman, MD, Steven Rosen, MD, Larry W Kwak, MD PhD, Swaminathan P. Iyer, MD

Blood (2019) 134 (Supplement_1): 4023.

https://doi.org/10.1182/blood-2019-123166

Published: 2019

Journal Articles

Aberrant SYK Expression As a Potential Therapeutic Target in T/NK Cell Neoplasms

Jing-Ping Zhang, PhD, Qi Gao, MLS, Alexander Chan, MD, Wenbin Xiao, MD PhD, Sary El Daker, PhD, Mikhail Roshal, MD PhD, Ahmet Dogan, MD PhD

Blood (2019) 134 (Supplement_1): 3978.

https://doi.org/10.1182/blood-2019-130406

Published: 2019

Journal Articles

Central Nervous System Involvement in Peripheral T-Cell Lymphoma

Sangeetha Gandhi, MBBS, N. Nora Bennani, MD, Sonia Fortin, Thomas M. Habermann, MD, Patrick Johnston, MD, James R. Cerhan, MD PhD, Kay M. Ristow, BS, Carrie A. Thompson, MD, Grzegorz Nowakowski, MD, Yi Lin, MD PhD, Jose C Villasboas, MD, Luis Porrata, MD, Thomas E. Witzig, MD, Ivana Micallef, MD, David J Inwards, MD, Stephen M Ansell, MD PhD, Jonas Paludo, MD

Blood (2019) 134 (Supplement_1): 5293.

https://doi.org/10.1182/blood-2019-131965

Published: 2019

Journal Articles

Central Nervous System Relapse in Patients with Peripheral T-Cell Lymphoma

Hyehyun Jeong, MD, Jung Yong Hong, Dok Hyun Yoon, Shin Kim, Jung Sun Park, Sang Wook Lee, Chan Sik Park, MD, Jin-Sook Ryu, Jooryung Huh, Cheolwon Suh

Blood (2018) 132 (Supplement 1): 5346.

https://doi.org/10.1182/blood-2018-99-119980

Published: 2018

Journal Articles

The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas

Blood (2018) 132 (Supplement 1): 997.

https://doi.org/10.1182/blood-2018-99-110563

Published: 2018

Journal Articles

Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for Autologous Hematopoietic CELL Transplantation (AHCT) in Patients with Mature T-CELL NON-Hodgkin Lymphoma, the "a-TAC-BEAM Regimen"

Jasmine Zain, MD, Jennifer Simpson, Joycelynne Palmer, Jeffrey Wong, MD, Savita Dandapani, MD PhD, David Colcher, PhD, Nicole Karras, MD, Alex F. Herrera, MD, Amandeep Salhotra, MD, Auayporn P. Nademanee, MDBS, Ryotaro Nakamura, MD, Eileen P. Smith, MD, Ni-Chun Tsai, David Yamauchi, MD, Kofi Poku, PharmD, Van Biglang-awa, PharmD, John E. Shively

Blood (2018) 132 (Supplement 1): 611.

https://doi.org/10.1182/blood-2018-99-116907

Published: 2018

Journal Articles

Intraepithelial Lymphocytosis of the Resection Margin in the Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma

Mi Hwa Heo, Hye Ra Jung, Young Rok Do, PhD MD, Jung-Sook Ha, MD PhD, Hyera Kim, Do-Hoon Kim, Jin Young Kim

Blood (2018) 132 (Supplement 1): 5317.

https://doi.org/10.1182/blood-2018-99-115639

Published: 2018

Journal Articles

RDW Is a Prognostic Marker for Patients with Aggressive Peripheral T-Cell Lymphoma

Brady E. Beltrán, MD, Denisse A. Castro, MD, Yesenia M. Huerta- Collado, MD, Eduardo Sotomayor, MD, Jorge J. Castillo, MD

Blood (2018) 132 (Supplement 1): 5364.

https://doi.org/10.1182/blood-2018-99-113236

Published: 2018

Journal Articles

Prognostic Value of Interim and End-of-Treatment PET-CT in Patients with Mature T-Cell and NK-Cell Lymphomas: A 10-Year Single Institution Study

Akihiro Kitadate, MD PhD, Kota Fukumoto, MD, Hiroki Kobayashi, MD, Yoshiaki Abe, Kentaro Narita, MD, Daisuke Miura, MD, Masami Takeuchi, MD, Kosei Matsue, MD PhD

Blood (2018) 132 (Supplement 1): 2930.

https://doi.org/10.1182/blood-2018-99-113746

Published: 2018

Journal Articles

A Patient Derived Xenograft As a Preclinical Model for Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma

Dachuan Huang, PhD, Wan Lu Pang, Daryl Ming Zhe Cheah, Yurike Laurensia, Jing Quan Lim, PhD, Soo Yong Tan, Tiffany Tang, MBBS, MRCP, Soon Thye Lim, Choon Kiat Ong, PhD

Blood (2018) 132 (Supplement 1): 2949.

https://doi.org/10.1182/blood-2018-99-110899

Published: 2018

Journal Articles

A Multicenter Retrospective Analysis of Clinicopathologic Features of Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma

Jun Ho Yi, MD PhD, Lee Gyeong-Won, Young Rok Do, PhD MD, Hong Jung Yong, Cheolwon Suh, Yoon Seok Choi, MD, Seong Yoon Lee, MD, Byeong Seok Sohn, MD PhD, Byung-Su Kim, MD PhD, Seok Jin Kim, MD PhD, Won-Seog Kim

Blood (2018) 132 (Supplement 1): 2909.

https://doi.org/10.1182/blood-2018-99-117880

Published: 2018

Journal Articles

Multicentric MFI30 Study: Standardization of CD30 Expression By Flow Cytometry in Non-Hodgkin Lymphoma

Agathe Pruvot Debliquis, pharmD, Lucile Baseggio, MD, Marie-Christine Jacob, Sabrina Bouyer, Franck Genevieve, MD PhD, Julien Guy, MD, Caroline Mayeur-Rousse, MD, Nicolas Chapuis, PharmD, PhD, Hind Bennani, Thomas Matthes, MD, Bernard Drenou

Blood (2018) 132 (Supplement 1): 2869.

https://doi.org/10.1182/blood-2018-99-115990

Published: 2018

Journal Articles

Monomorphic epitheliotropic intestinal T-cell lymphoma involving the central nervous system

Yasushi Kubota, Kana Kusaba

Blood (2018) 131 (15): 1765.

https://doi.org/10.1182/blood-2017-11-819136

Published: 2018

Journal Articles

Outcomes in Patients with Enteropathy-Associated T-Cell Lymphoma (EATL) and Hepatosplenic T-Cell Lymphoma (HSTCL): A Population Based Analysis Using the SEER Data

Mukhija Dhruvika, Tomas Radivoyevitch, PhD, Brian T. Hill, MD PhD, Robert M. Dean, MD, Brad Pohlman, MD, Deepa Jagadeesh, MDMPH

Blood (2017) 130 (Supplement 1): 2805.

https://doi.org/10.1182/blood.V130.Suppl_1.2805.2805

Published: 2017

Journal Articles

NKp46 Is a Useful Diagnostic Biomarker in Gastrointestinal T-Cell Lymphoproliferative Diseases and Constitutes a Therapeutic Target. a Celac Network Study

Morgane Cheminant, MD, Julie Bruneau, MD PhD, Georgia Malamut, MD PhD, David Sibon, Nicolas Guegan, Sascha Cording, PhD, Amélie Trinquand, MD PhD, Nicole Brousse, MD PhD, Sherine Khater, MD, Elizabeth A. Macintyre, PhD FRCP, FRCPath, Vahid Asnafi, MD PhD, Laurent Pouyet, PhD, Florence Lhospice, PharmD, Thierry Jo Molina, MDPhD, Bertrand Meresse, PhD, Christophe Cellier, MD PhD, Nadine Cerf-Bensussan, MD PhD, Olivier Hermine, MD PhD

Blood (2017) 130 (Supplement 1): 2820.

https://doi.org/10.1182/blood.V130.Suppl_1.2820.2820

Published: 2017

Journal Articles

Five-Year Survival Results: Frontline Brentuximab Vedotin in Combination with CHP in Patients with CD30-Expressing Peripheral T-Cell Lymphomas

Michelle A. Fanale, MD, Steven M. Horwitz, MD, Andres Forero-Torres, MD, Nancy L. Bartlett, MD, Ranjana H. Advani, MD, Barbara Pro, MD, Robert W. Chen, MD, Andrew Davies, PhD, Tim M. Illidge, MDPhD, Mayur Uttarwar, Dirk Huebner, MD, Hong Ren, MD, Andrei R. Shustov, MD

Blood (2017) 130 (Supplement 1): 2790.

https://doi.org/10.1182/blood.V130.Suppl_1.2790.2790

Published: 2017

Journal Articles

Bone Marrow Examination of Malignant Lymphomas in Korea: Eleven-Year Experience in a Single Institution

Woo Jae Kwoun, MD, Jeong-Yeal Ahn, MD, Ja Young Seo, MD, Jae Hoon Lee, MD PhD, Kwai Han Yoo, MD

Blood (2017) 130 (Supplement 1): 5147.

https://doi.org/10.1182/blood.V130.Suppl_1.5147.5147

Published: 2017

NARROW

A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

STAT3 Mutations and Anemia with Pure Red Cell Aplasia Are the Distinctive Features of T Cell Receptor Gamma Delta Type Large Granular Lymphocyte Leukemia

Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation

Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas

Aberrant SYK Expression As a Potential Therapeutic Target in T/NK Cell Neoplasms

Central Nervous System Involvement in Peripheral T-Cell Lymphoma

Central Nervous System Relapse in Patients with Peripheral T-Cell Lymphoma

The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas

Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for Autologous Hematopoietic CELL Transplantation (AHCT) in Patients with Mature T-CELL NON-Hodgkin Lymphoma, the "a-TAC-BEAM Regimen"

Intraepithelial Lymphocytosis of the Resection Margin in the Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma

RDW Is a Prognostic Marker for Patients with Aggressive Peripheral T-Cell Lymphoma

Prognostic Value of Interim and End-of-Treatment PET-CT in Patients with Mature T-Cell and NK-Cell Lymphomas: A 10-Year Single Institution Study

A Patient Derived Xenograft As a Preclinical Model for Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma

A Multicenter Retrospective Analysis of Clinicopathologic Features of Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma

Multicentric MFI30 Study: Standardization of CD30 Expression By Flow Cytometry in Non-Hodgkin Lymphoma

Monomorphic epitheliotropic intestinal T-cell lymphoma involving the central nervous system

Outcomes in Patients with Enteropathy-Associated T-Cell Lymphoma (EATL) and Hepatosplenic T-Cell Lymphoma (HSTCL): A Population Based Analysis Using the SEER Data

NKp46 Is a Useful Diagnostic Biomarker in Gastrointestinal T-Cell Lymphoproliferative Diseases and Constitutes a Therapeutic Target. a Celac Network Study

Five-Year Survival Results: Frontline Brentuximab Vedotin in Combination with CHP in Patients with CD30-Expressing Peripheral T-Cell Lymphomas

Bone Marrow Examination of Malignant Lymphomas in Korea: Eleven-Year Experience in a Single Institution

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only